Alnylam is a global biopharmaceutical company and the leader in RNAi therapeutics - an innovative class of medicines which "silence" or turn off the genes that cause/contribute to disease. We recognize the important role that social media plays in the lives of the people and communities we seek to serve. Having a presence on social media channels provides us an unique opportunity to inform, educate and engage with patients, families, caregivers, healthcare professionals, researchers, potential employees, investors and anyone else who’s interested in what we’re doing, and we are committed to interacting with all stakeholders legally, ethically and in accordance with regulatory standards. Community Guidelines:
We invite you to follow us and engage with our content, however please note that by replying to or commenting on our social media posts or by following our social media channels, you are agreeing to abide by and are subject to our Social Media Community Guidelines which you can review here: https://www.alnylam.com/social-media-community-guidelines. These guidelines apply in addition to the Terms and Conditions or other legal notices specific to each social media channel. Adverse Events/Product Complaints:
This Alnylam page is not an appropriate place to report adverse events (e.g., side-effects) or product complaints. If you wish to report an adverse event or product complaint, you can report them directly to your healthcare provider or email us at [email protected] or in Japan, [email protected]. Compassionate Use/Access to Investigational Medicines:
We understand that there are seriously ill patients who will not be eligible for our clinical trials and may not have options for alternative therapies, including investigational therapies in trials being conducted by other sponsors. In these circumstances, Alnylam will consider providing a requesting physician access to a specific Alnylam investigational therapy, for the treatment of an individual patient outside of a clinical trial (compassionate use request), or through an Alnylam early access program (EAP) when certain conditions are met. Learn more at https://www.alnylam.com/medical-professional-resources/early-access-program
Privacy:
Alnylam is committed to your privacy and we invite you to learn more about our privacy policies here: https://alnylampolicies.com/privacy. Please note that we will never request personal information (birthdates, email addresses, mailing addresses, social security numbers, bank account information, etc.) Careers/Hiring:
Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms (i.e. Google hangouts, WhatsApp, Facebook, etc.). Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in “.com.” Please do not provide any personal information if you receive a suspicious inquiry or job offer. If you suspect any fraudulent activity or misrepresentation in connection with an Alnylam job opportunity, please report it to [email protected]. Alnylam is an equal opportunity employer and welcomes all job applicants. All qualified applicants will receive consideration for employment without discrimination on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status, disability, or any other factors prohibited by law. Please see additional information about careers at Alnylam and current job openings here: https://www.alnylam.com/careers
Contact Us:
For other inquiries, including but not limited to information about our products, programs, clinical trials, grants/giving, and media relations, please see our Contact Us page here: https://www.alnylam.com/contact-us for the most appropriate way to contact us.
